Summary & Overview
HCPCS J9246: Injection, Melphalan (EvoMelA), 1 mg
HCPCS Level II code J9246 denotes a 1 mg injection of melphalan (EvoMelA), an intravenously administered alkylating chemotherapy agent used in oncologic treatment. Nationally, accurate coding for high-cost injectable drugs like melphalan is essential for claims processing, formulary management, and tracking utilization of specialty therapies in outpatient oncology settings.
This analysis covers major national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J9246 represents clinically and operationally, plus guidance on the types of benchmarks and policy considerations typically associated with HCPCS drug codes. Content addresses payer coverage patterns, billing practice considerations, and the clinical context for melphalan injections in outpatient infusion centers and hospital outpatient departments.
The publication outlines the expected service setting, common reporting practices, and areas where payers often set specific prior authorization or reimbursement policies for specialty oncology drugs. Where input data is unavailable, the report notes that specific payer policy details or utilization benchmarks are not present in the provided information.
Billing Code Overview
HCPCS Level II code J9246 describes an injection of melphalan (EvoMelA), 1 mg. This code represents a cytotoxic chemotherapy drug administered by injection for oncologic indications. The service type is injectable chemotherapy administration, and the typical site of service is an outpatient infusion center, hospital outpatient department, or clinic where parenteral oncology therapies are delivered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 62-year-old with newly diagnosed multiple myeloma or a relapsed/refractory plasma cell dyscrasia admitted for high-dose chemotherapy conditioning prior to autologous hematopoietic stem cell transplant (ASCT) or receiving intralesional or systemic therapy for refractory hematologic malignancy. The patient is assessed by hematology/oncology, has baseline labs including CBC, CMP, and organ-function testing, and consents to chemotherapy. Melphalan (J9246, 1 mg unit) is prepared in pharmacy under sterile technique and delivered to the infusion suite or inpatient oncology unit. Administration occurs via peripheral IV or central venous access (PICC, port-a-cath) as a single-agent infusion or as part of a conditioning regimen; dosing is weight- or body-surface-area–based and documented in mg/kg or total mg with the number of J9246 units billed accordingly. Nursing documents infusion start/stop times, lot and vial numbers, and patient tolerance; premedication and supportive care (antiemetics, hydration) are provided per protocol. Post-infusion monitoring includes vitals, laboratory surveillance for myelosuppression, and coordination of stem cell infusion when used for conditioning. Billing uses J9246 per 1 mg increment, with relevant modifiers applied for circumstances such as separate professional services, discontinued infusion, or drug wastage.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|